A recent report has claimed that an anti-cholesterol drug, TriLipix doesn’t work better than a generic medicine to protect against heart attacks or strokes. TriLipix is manufactured by Abbott Laboratories, which may face an adverse impact of the report. The report was prepared by the advisory panel of The U. S. Food and drug Administration.

TriLipix is a fibrate that reduces the blood fats called triglycerides while enhancing good cholesterol in the body and is approved by the FDA to use with statins like Lipitor and Zocor, which decreases the bad cholesterol.

The results were based on the comparison between Abbott’s TriCor, an older version of TriLipix also known as fenofibrate and the generic cholesterol pill, simvastatin.

After the release of the report, the FDA has asked the advisory panel to weigh several options including: whether TriLipix should be withdrawn for use with a statin, continue to be used with a statin with data from the study added to the prescribing information, tested in a new study, or face no changes.

The FDA is focusing on the effectiveness of TriLipix because Tricor is not approved for use in combination with a statin treatment.